Molecularinstruments
1 known investors
Molecular Instruments develops HCR-based in situ hybridization and immunofluorescence products for detecting and quantifying RNA and protein targets in biological samples. Its enzyme-free signal amplification technology supports multiplex RNA-FISH and same-species antibody immunofluorescence for life science researchers.
Investors · 1
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $150K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Molecularinstruments do?
- Molecular Instruments develops HCR-based in situ hybridization and immunofluorescence products for detecting and quantifying RNA and protein targets in biological samples. Its enzyme-free signal amplification technology supports multiplex RNA-FISH and same-species antibody immunofluorescence for life science researchers.
- Who are Molecularinstruments's investors?
- Molecularinstruments's investors include FREEFLOW.